Immunovia Q3 net sales surge on PancreaSure uptake

Overview

• Sweden diagnostic firm's Q3 net sales rose sharply yr/yr, driven by PancreaSure test sales

• Operating loss narrowed compared to Q3 2025

• Company announced SEK 63 mln rights issue to fund US commercialization and clinical studies

Outlook

• Company awaits Medicare coverage decision for PancreaSure, which could expand future revenue

• Immunovia plans to use rights issue proceeds to fund US commercialization and clinical studies

• Company expects recent clinical results to support commercial adoption and reimbursement efforts

Result Drivers

• TEST ADOPTION - Co said increased uptake of PancreaSure test and addition of high-risk surveillance centers drove Q3 sales, per CEO Jeff Borcherding

• LOWER STUDY COSTS - Co said reduced spending on clinical studies lowered operating cash burn in Q3

Company press release:

Key Details

Analyst Coverage

• Wall Street's median 12-month price target for Immunovia AB (publ) is SEK0.43, about 758.3% above its October 30 closing price of SEK0.05

Reuters Recommended Reads

• Oct 30 - Sweden's Invisio Q3 revenue misses estimates

• Oct 30 - Canada's Aurinia Q3 revenue rises 14% on LUPKYNIS sales

• Oct 30 - AstraZeneca CEO strikes bullish tone on pipeline as stock rallies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)